Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 22,503 matching trials from the live ClinicalTrials.gov search.

Filters: Houston, Texas Clear all

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 1,153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 160
States / cities: Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 124 more

Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer
Interventions: Atezolizumab, Bevacizumab; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Skin and Soft Tissue (SST) Infection
Interventions: Arm 1: Routine Care, Arm 2: INSPIRE Stewardship Bundle for Skin and Soft Tissue Infection; Other
Lead sponsor: Harvard Pilgrim Health Care; Other
Eligibility: 18 Years and older
Enrollment: 118,562 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 102
States / cities: Riverside, California • San Jose, California • Thousand Oaks, California + 80 more

Conditions: Astrocytoma, Oligodendroglioma
Interventions: Vorasidenib, Pembrolizumab; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: Non-Hodgkin's Lymphoma
Interventions: ABT-199, Rituximab, Bendamustine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 8
States / cities: La Jolla, California • Los Angeles, California • Atlanta, Georgia + 5 more

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: VX-864, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more

Conditions: Alzheimer's Disease
Interventions: Dimebon, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 93
States / cities: Mobile, Alabama • Northport, Alabama • Little Rock, Arkansas + 82 more

Conditions: Diarrhea
Interventions: Heat-Labile Enterotoxin of Escherichia coli (LT), Placebo; Biological
Lead sponsor: Intercell USA, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 13
States / cities: Long Beach, California • Chicago, Illinois • Baltimore, Maryland + 9 more

Conditions: Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic
Interventions: ABC294640, Hydroxychloroquine Sulfate 200 MG; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Phoenix, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more

Conditions: Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
Interventions: NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane, NGM120 100mg with Gemcitabine and Abraxane, NGM120 100mg Q3W, Placebo; Biological · Other
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 20
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more

Conditions: Prostate Cancer
Interventions: Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 45
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more

Conditions: Primary Breast Cancer ER+ve, Primary Breast Cancer AR+ve TNBN
Interventions: Enzalutamide, Exemestane; Drug
Lead sponsor: Queen Mary University of London; Other
Eligibility: 18 Years and older · Female only
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: SARS-CoV-2, Influenza
Interventions: mRNA-1083, Placebo, Influenza Vaccine, COVID-19 Vaccine; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 8,061 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 146
States / cities: Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 122 more

Conditions: Head and Neck Cancer
Interventions: cisplatin, docetaxel, fluorouracil, radiation therapy; Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 94
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 61 more

Conditions: Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer, Anaplastic Thyroid Cancer, Other Solid Tumors
Interventions: PDR001; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 6
States / cities: Baltimore, Maryland • Boston, Massachusetts • Portland, Oregon + 3 more

Conditions: Sickle Cell Disease
Interventions: Osivelotor; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Months and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Baton Rouge, Louisiana • New Orleans, Louisiana • Madison, Mississippi + 2 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Obinutuzumab, ABBV-453; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Duarte, California • Irvine, California • Billings, Montana + 3 more

Conditions: Coronary Artery Bypass Grafting
Interventions: Vein Harvesting Procedures; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 16
States / cities: Tucson, Arizona • San Francisco, California • Gainesville, Florida + 13 more

Conditions: Type 1 Diabetes
Interventions: Type 1 Doing Well (T1DW) Program, Diabetes-Related Information and Resources Program; Behavioral · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 99 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Knowledge Representation, Knowledge Modeling
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 21 Years to 60 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Fingolimod, Disease Modifying therapy; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 122
States / cities: Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 111 more

Conditions: Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
Interventions: BMN 110; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 7 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Oakland, California • Chicago, Illinois • New York, New York + 1 more

Conditions: Intracerebral Hemorrhage
Interventions: rt-PA; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 56
States / cities: Birmingham, Alabama • Phoenix, Arizona • Carmichael, California + 46 more

Conditions: Malignant Glioma
Interventions: Biopsy Procedure, Magnetic Resonance Imaging, Radiation Therapy, Selinexor; Procedure · Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 111
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 93 more

Search by objective public record fields.

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

INSPIRE Trial for Skin and Soft Tissue Infections

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease

ETEC Logistics Trial (TREK)

A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Randomized Endo-Vein Graft Prospective

EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes

Formalizing a Conceptual Framework of Work Domain Knowledge

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome

Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)